Leap Therapeutics, H.C. Wainwright

Leap Therapeutics stock rating cut by H.C. Wainwright to Neutral
H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock rating from Buy to Neutral. The downgrade has intensified pressure on LPTX shares,
Why Leap Therapeutics, Inc.’s (LPTX) Stock Is Down 71.11%
Leap Therapeutics, Inc.’s LPTX share price has dipped by 71.11%, which has investors questioning if this is right time to buy.
Leap Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Leap Therapeutics (LPTX) to Neutral from Buy without a price target after the company presented clinical data
Leap Therapeutics cut to Neutral at Baird after mid-stage trial setback
Leap Therapeutics (NASDAQ:LPTX) fell ~12% on Wednesday as Baird downgraded the stock after the biotech said its lead candidate, sirexatamab, generated disappointing data in a mid-stage trial for gastric cancer.
HC Wainwright & Co. Downgrades Leap Therapeutics (LPTX)
Fintel reports that on January 29, 2025, HC Wainwright & Co. downgraded their outlook for Leap Therapeutics (NasdaqCM:LPTX) from Buy to Neutral. Analyst Price Forecast Suggests 1,441.50% Upside As of January 28,
Leap Therapeutics downgraded to Neutral from Outperform at Baird
Baird downgraded Leap Therapeutics (LPTX) to Neutral from Outperform with a price target of $1.25, down from $9, after after the company
Leap Therapeutics: 2 Cancer Trials Disappoint, But There Is A Silver Lining
Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...
Leap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancer
Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its ...
Leap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug Results
Shares of Leap Therapeutics slid after disappointing initial data from two mid-stage clinical trials of its oncology treatment, resulting in the discontinuation of one clinical program.
Leap scraps late-stage plans for gastric cancer therapy after mid-stage setback
Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...
The Pharma Letter1d
Leap halts gastric cancer program, changes course
Leap Therapeutics is discontinuing the development of its anti-DKK1 antibody sirexatamab in gastric cancer after the drug ...
FierceBiotech2d
Leap crashes as midphase data mark end of gastric cancer program
Leap Therapeutics has come crashing down to earth. The biotech axed plans to advance into phase 3 in gastric cancer on the basis of midstage data, sending its stock down 60% to below $1, but it is ...
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data from Part B of the DeFianCe study ...
Stocktwits on MSN2d
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipeline
Shares of Leap Therapeutics, Inc. nosedived more than 70% to an all-time low on Tuesday, making them the top loser across U.S ...